Goldman Sachs
VTVT icon

Goldman Sachs’s vTv Therapeutics VTVT Stock Holding History

Goldman Sachs’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,350
Closed -$529K – 7031
2026
Q1 		$529K Buy
13,350
+7,819
+141% +$284K ﹤0.01% 5567
2025
Q4 		$221K Buy
+5,531
New +$154K ﹤0.01% 6003
2021
Q4 		– Sell
-603
Closed -$37K – 6730
2021
Q3 		$37K Sell
603
-224
-27% -$16.9K ﹤0.01% 6097
2021
Q2 		$75K Sell
827
-747
-47% -$75.7K ﹤0.01% 6014
2021
Q1 		$178K Buy
+1,574
New +$155K ﹤0.01% 5685
2020
Q3 		– Sell
-477
Closed -$43K – 5556
2020
Q2 		$43K Buy
477
+19
+4% +$1.88K ﹤0.01% 5075
2020
Q1 		$35K Buy
+458
New +$44K ﹤0.01% 5087
2019
Q4 		– Sell
-267
Closed -$17K – 5424
2019
Q3 		$17K Buy
+267
New +$15.1K ﹤0.01% 5115
2018
Q4 		– Sell
-374
Closed -$12K – 5708
2018
Q3 		$12K Sell
374
-764
-67% -$35.8K ﹤0.01% 5461
2018
Q2 		$70K Buy
+1,138
New +$84.1K ﹤0.01% 5286

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's VTVT Position: Q2 2026 in Review

Goldman Sachs sold out of vTv Therapeutics (VTVT) in Q2 2026, closing a stake of 13,350 shares — an estimated $529K sold.

Goldman Sachs first reported a position in VTVT in Q2 2018 and held it in 10 quarters. The position peaked at $529K in Q1 2026. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Goldman Sachs reported no remaining vTv Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 13,350 vTv Therapeutics shares in Q2 2026, an estimated $529K.
  • Goldman Sachs first reported a position in vTv Therapeutics in Q2 2018 and held it in 10 quarters.
  • Goldman Sachs's vTv Therapeutics position peaked at $529K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.